Cognitive outcomes of the bipolar depression electrical treatment trial (BETTER): a randomized, double-blind, sham-controlled study
Autor: | Paulo A. Lotufo, Stephan Goerigk, Wagner F. Gattaz, Gabriel Tortella, Adriano Fernandes da Silva, Isabela M. Benseñor, Bernardo Sampaio-Junior, Lucas Borrione, Marina Moreno, Beny Lafer, Andre R. Brunoni, Adriano H. Moffa, Rodrigo Machado-Vieira |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Transcranial direct-current stimulation Working memory business.industry medicine.medical_treatment Neuropsychology Cognition General Medicine medicine.disease 030227 psychiatry Clinical trial 03 medical and health sciences Psychiatry and Mental health 0302 clinical medicine Physical medicine and rehabilitation medicine Pharmacology (medical) Effects of sleep deprivation on cognitive performance Bipolar disorder Prefrontal cortex business 030217 neurology & neurosurgery Biological Psychiatry |
Zdroj: | European Archives of Psychiatry and Clinical Neuroscience. 271:93-100 |
ISSN: | 1433-8491 0940-1334 0215-2878 |
DOI: | 10.1007/s00406-020-01121-2 |
Popis: | Bipolar depression is associated with marked cognitive deficits. Pharmacological treatments for this condition are limited and may aggravate depressive and cognitive symptoms. Therefore, therapeutic interventions that preserve adequate cognitive functioning are necessary. Our previous results demonstrated significant clinical efficacy of transcranial direct current stimulation (tDCS) in the Bipolar Depression Electrical Treatment Trial (BETTER). Here, cognitive outcomes of this study are reported. We randomized 59 patients with bipolar disorder I or II in an acute depressive episode to receive active (12 2 mA, 30-min, anodal-left, cathodal-right prefrontal cortex tDCS sessions) or sham tDCS. Patients were on stable pharmacological regimen for at least 2 weeks. A battery of 12 neuropsychological assessments in five cognitive domains (attention and processing speed, memory, language, inhibitory control, and working memory and executive function) was performed at baseline, after two weeks and at endpoint (week 6). No significant differences between groups over 6 weeks of treatment were observed for any cognitive outcomes. Moreover, no decrease in cognitive performance was observed. Our findings warrant further replication in larger studies. Trial Registration: clinicaltrials.gov Identifier: NCT02152878 |
Databáze: | OpenAIRE |
Externí odkaz: |